Pharmacogenetics and pharmacogemics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechlogy and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.
Bernard Lerer is Professor of Psychiatry and Director of the Biological Psychiatry Laboratory at Hadassah - Hebrew Medical Center in Jerusalem. He is Director of the National Institute for Psychobiology in Israel, and Editor-in-Chief of the International Journal of Neuropsychopharmacology.